56th International Conference on Medicinal Chemistry 56èmes Rencontres Internationales de Chimie Thérapeutique
Bordeaux, France July 1-3, 2020
A Long Quest for DNA Methylation Inhibitors and their Use to Kill Resistant Malaria Parasites
Dr Paola ARIMONDO
INSTITUT PASTEUR - CNRS UMR3523, Paris, France Read more
Dr Paola ARIMONDO
Dr Paola B. Arimondo studied Chemistry at the University of Pisa (Scuola Normale Superiore, Italy) and received her Ph.D in Biophysics at the MNHN in Paris. Paola Arimondo is Director of Research at CNRS and her research focuses on the interactions between nucleic acids and proteins and their modulation by small chemical molecules. In particular, after a six-month sabbatical in 2005 at the University of California in Berkeley, she develops innovative chemical strategies aiming at the epigenetic control of gene expression in cancers. In 2011, Paola Arimondo was recruited to lead the Laboratory of Epigenetic Targeting of Cancer (ETaC) USR3388, a 5-years joint public-private Laboratory between the CNRS and Pierre Fabre Laboratories, in Toulouse, France. She developed projects at the interface of Chemistry and Biology to discover chemical modulators of DNA and histone methylation in cancer. In 2016, she was appointed Oversea Fellow at the Churchill College in Cambridge UK. In 2018 she started the Epigenetic Chemical Biology Unit at the Institut Pasteur, where she continues to explore the chemical targeting of the epigenetic regulation to fight human diseases. Her research focus now spans beyond cancer, to the field of infectious diseases.
Multi-target-Directed Ligands to Combat Neurodegenerative Diseases: All-In-One and One-For-All
Maria Laura Bolognesi is Professor of Medicinal Chemistry, Director of the Chemistry and Pharmaceutical Technologies degree program and Rector Delegate for Latin American International Relations at the University of Bologna. She obtained her PhD under the mentorship of Professor Carlo Melchiorre in 1996 and carried out postdoctoral work at the University of Minnesota with Professor Philip S. Portoghese. Her research explores the development of small molecules in the neurodegenerative and neglected tropical disease therapeutic areas. Maria Laura was awarded the positions of Distinguished Visiting Professor at the Complutense University of Madrid in 2009, Pesquisador Visitante Especial at the University of Brasilia in 2014 and Professeur Invité at Université Caen Normandie in 2018. She is an Associate Editor of Journal of Medicinal Chemistry and serves in the Advisory Board of the European Federation of Medicinal Chemistry
Daridorexant - A Dual Orexin Receptor Antagonist
Dr Christoph BOSS
IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland Read more
Dr Christoph BOSS
Christoph Boss is Vice President, Head of Drug Discovery Chemistry
Education: PhD, synthetic organic chemistry at the University of Bern, Switzerland followed by post-doctoral training at The Scripps Research Institute (TSRI) in LaJolla, California, USA.
Professional background: From 1999 until 2012, various positions of increasing responsibility in Actelion's drug discovery chemistry department contributing to the identification of several lead compounds including macitentan for PAH and ACT-541468 for insomnia. Senior Group Leader Chemistry Technologies 2012-2017. Joined Idorsia when the company was established in June 2017 as a Senior Group Leader in Drug Discovery Chemistry. Head of Drug Discovery Chemistry at Idorsia since July 2019.
The Genetic Code in Two Dimensions
Prof. Thomas CARELL
LUDWIG-MAXIMILIANS-UNIVERSITY, Munich, Germany Read more
Thomas Carell was born in Herford (Germany) in 1966. He is married and father of three children. His academic career in chemistry began at the Universities of Münster and Heidelberg. In 1993, he obtained his doctorate with Prof. H. A. Staab at the Max-Planck Institute of Medical Research.
After postdoctoral training with Prof. J. Rebek at MIT (Cambridge, USA) from 1993 – 1995, Thomas Carell moved to the ETH Zürich (Switzerland) into the group of Prof. F. Diederich to start independent research. He obtained his habilitation in 1999.
In 2000, he accepted a full professor position for Organic Chemistry at the Philipps-Universität in Marburg (Germany). In 2004, he moved to the Ludwig-Maximilians-Universität (LMU) in Munich (Germany) where he is heading a research group in chemical biology focused to analyze the chemistry of epigenetic programming in DNA and RNA.
Thomas Carell is a member of the German National Academy Leopoldina and of the Berlin-Brandenburgische Academy of Arts and Sciences. He is the recipient of the Cross of Merit from the Federal Republic of Germany.
Bioorthogonal Protein Activation in Living Systems
- Peng Chen, Professor of Chemical Biology, Peking University, Beijing, China
- Chemical Biology, Bioorthogonal Reactions
2014-present, Professor of Chemical Biology, Peking University
2009-2014, Investigator of Chemical Biology, Peking University
2007-2009, Postdoctoral Scientist, The Scripps Research Institute
2002-2007 Ph.D in Chemistry, The University of Chicago
1998-2002 B.S. in Chemistry, Peking University
Nanomedicine for the Treatment of Cancer and Neurological Disorders
Patrick COUVREUR, pharmacist and PhD from the Université Catholique de Louvain, is an Emeritus Professor at Paris-Saclay University, member of the Académie des Sciences and holder of the chair of “Innovations Technologiques” (2009-2010) at the Collège de France. He is the President 2020 of the French National Academy of Pharmacy. Prof COUVREUR’s contributions are in the field of drug delivery and nanomedicine. He founded three start-up companies (Bioalliance, entering the stock market in 2005, Medsqual and Squal Pharma) and developed an anticancer nanomedicine reaching phase III clinical trial for the treatment of the hepatocarcinoma. Apart from the Académie des Sciences, he is also appointed as a foreign member of two of the three US National Academies (Engineering and Medicine).
Recent Advances in Breast Cancer Treatment: Discovery of SAR439859, a Selective Estrogen Receptor Degrader for the Treatment of Estrogen-Receptor-Positive Breast Cancer.
Youssef El Ahmad is a Group leader of Medicinal Chemistry at Sanofi.
After a MsC degree from Lebanese University and a PhD in Pharmaceutical Sciences from the Faculty of Pharmacy of Paris XI University, he joined the Medicinal Chemistry department at Sanofi 30 years ago.
During his career, he supports and leads projects in CNS, anti-infective and oncology fields and contributes to the development of several clinical candidates especially for cancer treatment.
In this congress, he presents the “Recent Advances in Breast Cancer Treatment: Discovery of SAR439859, a Selective Estrogen Receptor Degrader for the Treatment of Estrogen-Receptor-Positive Breast Cancer”.
Peptide-Derived Ligands with Tailored Flexibility and their Use for Intracellular Targets
Prof. Tom GROSSMANN
VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands Read more
Prof. Tom GROSSMANN
Tom Grossmann holds the Chair of Biomimetic Chemistry at the VU University Amsterdam. He studied chemistry at the Humboldt University Berlin, including undergraduate research with Peter Vollhardt at the University of California Berkeley. In 2008, he received his PhD with Oliver Seitz at the Humboldt University Berlin. After postdoctoral research in the group of Gregory Verdine at Harvard University, he became group leader at the Technical University and the Chemical Genomics Centre in Dortmund. Since 2016, he is full professor at the VU University Amsterdam, currently being supported by an ERC Starting Grant.
Ligand-directed Labeling of Endogenous Proteins in Live Cells
Prof. Itaru HAMACHI
KYOTO UNIVERSITY, Japan
Expanding the Genetic Code - Chemistry in Living Systems
Prof. Kathrin LANG
TECHNICAL UNIVERSITY OF MUNICH, Garching, Germany
Biomimetic Chemistry of Human RNAi Therapeutics
Dr Mano MANOHARAN
ALNYLAM PHARMACEUTICALS, Cambridge, United States Read more
Dr Mano MANOHARAN
Dr Muthiah (Mano) Manoharan serves as a Senior Vice President of Drug Innovation, a Scientific Advisory Board Member, and a Distinguished Research Scientist at Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. Dr. Manoharan has had a distinguished career as a world-leading chemist in the areas of oligonucleotide chemical modifications, conjugation chemistry, and delivery platforms (lipid nanoparticles, polymer conjugates, and complex-forming strategies). Dr. Manoharan and his research group designed, synthesized and demonstrated for the first time the human therapeutic applications of GalNAc-conjugated oligonucleotides at Alnylam, a platform that has revolutionized the nucleic acid-based therapeutics field with several compounds presently in the advanced clinical trials. He is an author of more than 215 publications (nearly 44,000 Google Scholar citations with an h-index of 96 and an i10-index of 375) and over 400 abstracts, as well as an inventor of over 240 issued U.S. patents.
Dr. Manoharan earned his Ph.D. in chemistry at the University of North Carolina, Chapel Hill with Professor Ernest Eliel in Organic Chemistry. He started working in the field of oligonucleotides at Yale University as a post-doctoral research associate with Professor John Gerlt.
Dr Manoharan has been recognized as the Lifetime Achievement Awardee of the Oligonucleotide Therapeutics Society for the year 2019. He received the M. L. Wolfrom Award from the American Chemical Society in 2007.
Title to be announced
Dr Darryl MCCONNELL
BOEHRINGER INGELHEIM RCV, Vienna, Austria
Sulfatase Inhibitors: From Concept to Clinical Trials and Beyond
Prof. Barry POTTER
UNIVERSITY OF OXFORD, Oxford, United Kingdom Read more
Prof. Barry POTTER
Barry Potter studied Chemistry at Oxford, completing a DPhil on enzyme-catalyzed phosphoryl transfer stereochemistry with a DSc in 1993. After postdocs in Oxford and at the Max-Planck-Institute in Göttingen, he was lecturer in Biological Chemistry at Leicester, winning a Lister Institute Fellowship, then moved to the chair of Medicinal Chemistry at Bath. Research interests are in mechanistic enzymology, signal transduction chemistry and anticancer drug discovery. He has published over 550 papers, is inventor of 45 granted US patents and has brought academically-discovered drugs to multiple human clinical trials with clinical benefit. In 2015 he became Professor of Medicinal & Biological Chemistry at Oxford. He has won four interdisciplinary RSC medals, the GSK International Achievement Award, a European Life Science Award, held the 2015 RSC Medicinal Chemistry Endowed Lectureship and won the 2018 Tu Youyou Award for his work in Medicinal and Natural Product Chemistry. He was elected to the Academy of Medical Sciences and Academia Europaea.
Targeting Protein-Protein Interactions in Receptor Complexes
Prof. Kristian STROMGAARD
UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark Read more
Prof. Kristian STROMGAARD
Professor Kristian Strømgaard graduated from the Royal Danish School of Pharmacy (1999), with part of the studies carried out at the Danish pharmaceutical company H. Lundbeck A/S and previous studies at University College London. He did his postdoctoral training at Columbia University (USA) and was subsequently appointed assistant professor at University of Copenhagen, and thereafter promoted to full professor in chemical biology 2006. His research spans chemistry and biology with focus on protein-protein interactions, including inlcuding peptide and protein engineering. In 2014 he was appointed Director of Center for Biopharmaceuticals at University of Copenhagen and 2016-17 he was a visting professor at Harvard Medical School. He is co-founder of the biotechnology company Avilex Pharma.
Identification of the Potent, Highly Selective and Orally Bioavailable ATR Inhibitor BAY 1895344